Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label ADME and absolute bioavailability study of IPI-145 in healthy male subjects
NL-OMON38629Phase 1Active, not recruiting
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of duvelisib in Inflammatory Disorders and hematopoietic malignancies, sponsored by Infinity Pharmaceuticals, Inc. Primary endpoints: Blood concentrations of radioactivity, Plasma concentrations of radioactivity and 10 more. Started Feb 2013; status: active, not recruiting.
02
Drugs
duvelisib
03
Conditions
Inflammatory Disordershematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON38629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38629.